Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TELO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.26% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.54M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.52 - 8.40 | Updated Date 06/29/2025 |
52 Weeks Range 1.52 - 8.40 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -391.62% | Return on Equity (TTM) -872.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46827162 | Price to Sales(TTM) - |
Enterprise Value 46827162 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 29762700 | Shares Floating 17618311 |
Shares Outstanding 29762700 | Shares Floating 17618311 | ||
Percent Insiders 34.17 | Percent Institutions 12.53 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Telomir Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on developing and commercializing Telomir-1, a novel small molecule compound targeting telomere length for age-related diseases. Founded relatively recently, its primary focus is on progressing Telomir-1 through clinical trials.
Core Business Areas
- Pharmaceutical Development: Research and development of Telomir-1 for treatment of age-related diseases.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of Telomir-1.
- Intellectual Property: Securing and maintaining intellectual property rights related to Telomir-1 and related technologies.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and business. Organizational structure is typical for a pre-clinical stage company, with departments focused on research, development, and administration.
Top Products and Market Share
Key Offerings
- Telomir-1: Telomir-1 is the primary product; a novel small molecule being developed for treatment of age-related diseases by targeting telomere length. It is currently in pre-clinical stage. Market share and revenue are currently nonexistent. Competitors include companies targeting aging with other approaches (e.g., senolytics, mTOR inhibitors).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on age-related diseases is growing, driven by aging populations and increased research into the biology of aging.
Positioning
Telomir Pharmaceuticals is positioned as a company developing a novel therapeutic approach to age-related diseases through telomere length modulation.
Total Addressable Market (TAM)
The TAM for age-related diseases is substantial, estimated in the hundreds of billions of dollars. Telomir's position is high-risk, high-reward, dependent on successful clinical trials.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (telomeres)
- Focused product pipeline (Telomir-1)
- Experienced management team
Weaknesses
- Pre-clinical stage
- High regulatory risk
- Limited financial resources
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other age-related diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies targeting aging
- Fundraising challenges
Competitors and Market Share
Key Competitors
- CRIS (Crispr Therapeutics)
- VERX (Vertex Pharmaceuticals)
- LLY (Eli Lilly and Company)
Competitive Landscape
Telomir faces substantial competition from established pharmaceutical companies and other biotechnology firms developing therapies for age-related diseases. Telomir's success depends on its ability to differentiate Telomir-1 and demonstrate clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal, typical of a pre-clinical stage company.
Future Projections: Future growth depends entirely on the success of Telomir-1 clinical trials and subsequent regulatory approvals.
Recent Initiatives: Recent initiatives likely include advancing Telomir-1 through pre-clinical studies and preparing for clinical trials.
Summary
Telomir Pharmaceuticals is a very high-risk, very high-reward, pre-clinical stage company focused on a novel approach to treating age-related diseases. Its success hinges on the successful development and commercialization of Telomir-1. Key strengths include its novel therapeutic target and experienced management. The company needs to overcome regulatory hurdles and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investing in pre-clinical stage companies involves substantial risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telomir Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2024-02-09 | Chairman of the Board & CEO Mr. Erez Aminov | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telomirpharma.com |
Full time employees - | Website https://telomirpharma.com | ||
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.